Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2010

01-09-2010 | Original Paper

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature

Authors: Halit Karaca, Ayhan Lale, Mustafa Dikilitas, Metin Ozkan, Ozlem Er

Published in: Medical Oncology | Issue 3/2010

Login to get access

Abstract

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor. İt has higher response rates and progression-free survival in patients with metastatic renal cell carcinoma (RCC) when compared with standard chemotherapy and interferon-α. We report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33-years-old man with metastatic RCC. At the sixth month of follow-up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life-threatening entity.
Literature
1.
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
2.
Ganesh SP, Blaine K, Jacob R. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4(4):163–70.
3.
Er O, Coşkun HS, Altınbaş M, et al. Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia. Urol Int. 2001;67:175–7.CrossRefPubMed
4.
Warren WD, Utz DC, Kelalis PP. Concurrence of hypernephroma and hypercalcemia. Ann Surg. 1971;174:863–5.CrossRefPubMed
5.
Mundy GR, Ibbotson KJ, D’Souza SM, et al. The hypercalcemia of cancer. N Engl J Med. 1984;310:1718–27.CrossRefPubMed
6.
Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.CrossRefPubMed
7.
Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005;23:240–55.
8.
Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471–8.PubMed
9.
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37.PubMed
10.
Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757–66.CrossRefPubMed
11.
O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–605.CrossRefPubMed
12.
Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma (abstract no. LBA3). J Clin Oncol. 2006;24(Suppl 18):930.
13.
Escuider B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol. 1999;17:2039–43.
14.
Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–63.CrossRefPubMed
15.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115–24.CrossRefPubMed
16.
Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287–95.PubMed
17.
Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with percyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338–40.PubMed
18.
Newman E, Bouvet M, Borgehi S, Herold D, Deftos L. Causes of hypercalcemia in a population of military veterans in the United States. Endocr Pract. 2006;12(5):535–41.PubMed
19.
Lee C, Yang C, Lam K, et al. Hypercalcemia in the emergency department. Am J Med Sci. 2006;331(3):119–23.CrossRefPubMed
20.
Vassilopoulou-Sellin R, Newman B, Taylor S, Guinee V. Incidence of hypercalcemia in the patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309–12.CrossRefPubMed
21.
Papworth K, Grankvist K, Ljungberg B, Rasmuson T. Parathyroid hormone-related protein and serum calcium in patient with renal cell carcinoma. Tumour Biol. 2005;2(4):201–6.CrossRef
22.
Chasan SA, Pothel RL, Huben RP. Management and prognostic significance of hypercalcemia in renal cell carcinoma. Urology. 1989;33:167–71.CrossRefPubMed
23.
Endo I, Inoue D. Treatment of malignancy-associated hypercalcemia. Clin Calcium. 2006;16(4):373–9.
24.
Ritch PS. Treatment of cancer-related hypercalcemia. Semin Oncol. 1990;17:26–33.PubMed
25.
Pepper K, Jaowattana U, Starsiak MD, et al. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature. Soc Gen Int Med. 2007;22:1042–6.CrossRef
26.
Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–18.CrossRefPubMed
Metadata
Title
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Authors
Halit Karaca
Ayhan Lale
Mustafa Dikilitas
Metin Ozkan
Ozlem Er
Publication date
01-09-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9327-4

Other articles of this Issue 3/2010

Medical Oncology 3/2010 Go to the issue

Original Paper

The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor β1 and tumor necrosis factor α

Original Paper

Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy

Original Paper

Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma

Original Paper

Low molecular weight fraction secreted by SKOV3 cells expands peripheral CD4+CD25+ regulatory T cells and enhances their suppressive capacity

Original Paper

Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases

Original Paper

Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits